By Bloomberg News Biotech firm RXRX is reportedly on the verge of being delisted, according to sources familiar with the matter. Mounting financial red flags, coupled with questionable compliance practices, have raised serious doubts about the company’s ability to remain on the exchange. Insiders say regulators have already begun reviewing RXRX’s recent filings, and if the findings don’t meet the required standards, a forced delisting could come sooner than expected. The company has yet to issue a formal response, further fueling speculation. Investors are fleeing, and market analysts warn that RXRX may be headed toward a full-scale collapse unless urgent corrective measures are taken.